Family Med

Your Article Summary

See Latest Articles

Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine
Cephalalgia, 09/08/09

Silberstein SDe et al. – Tonabersat was generally well tolerated, with dizziness and nausea the most common side–effects. Serious adverse events were uncommon, and no patient withdrew from either study because of adverse events. These results suggest a possible interplay between tonabersat pharmacokinetics (the relatively long time required to reach maximum plasma concentrations) and patient characteristics (previous triptan exposure) in the management of acute migraine attacks. Based on the pharmacokinetics and actions on cortical spreading depression, tonabersat may have potential value in migraine prophylaxis.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Beta-2 agonists in sport. Are the Anti-Doping rules meeting the needs of asthmatic athletes?
British Journal of Sports Medicine, 12/15/09

Combination therapy of statins and fibrates in the management of cardiovascular risk
Current Opinion in Lipidology, 12/15/09

Statins for Primary Prevention of Cardiovascular Mortality in Women: A Systematic Review and Meta-Analysis
Preventive Cardiology, 12/15/09

 See all of Clinical Pharmacology

Today in Critical Care/Emergency...keeping you current

Receive free subspecialty "5-minute updates" via email

Relation of Nausea and Vomiting in Acute Myocardial Infarction to Location of the Infarct
The American Journal of Cardiology, 12/15/09

Usefulness of Fragmented QRS on a 12-Lead Electrocardiogram in Acute Coronary Syndrome for Predicting Mortality
The American Journal of Cardiology, 12/15/09

Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events
European Heart Journal, 12/15/09

 See all of Critical Care/Emergency